Chromosome fragility in the buccal epithelium in patients with Fanconi anemia.
Adolescent
Adult
Biomarkers, Tumor
/ genetics
Child
Child, Preschool
Chromosome Fragility
/ genetics
DNA Damage
/ genetics
Epithelium
/ metabolism
Fanconi Anemia
/ drug therapy
Female
Genomic Instability
/ genetics
Humans
Male
Micronuclei, Chromosome-Defective
Micronucleus Tests
/ methods
Middle Aged
Mouth Mucosa
/ metabolism
Squamous Cell Carcinoma of Head and Neck
/ drug therapy
Young Adult
Biomarker
Buccal cells
Head and neck squamous cell carcinoma
Micronuclei
Journal
Cancer letters
ISSN: 1872-7980
Titre abrégé: Cancer Lett
Pays: Ireland
ID NLM: 7600053
Informations de publication
Date de publication:
01 03 2020
01 03 2020
Historique:
received:
31
07
2019
revised:
05
12
2019
accepted:
06
12
2019
pubmed:
13
12
2019
medline:
12
8
2020
entrez:
13
12
2019
Statut:
ppublish
Résumé
Fanconi anemia (FA) is a rare genome instability syndrome characterized by progressive bone marrow failure and predisposition to cancer, especially head and neck squamous cell carcinoma. Surgical resection is the standard of care for solid tumors, as patients with FA do not tolerate genotoxic chemotherapies or radiation, leading to poor prognosis. It is therefore imperative to develop chemoprevention strategies such as the identification of novel biomarkers to detect the formation of the tumor before its emergence and to use them in clinical trials aimed to counteract genome instability of patients with FA in tissues at risk. Micronuclei (MN) are chromosome fragments that are left behind in anaphase and appear in daughter cells as small additional nuclei. In this work, we analyzed MN frequencies in exfoliated buccal cells from 40 patients with FA and 24 controls. We found that MN frequency was significantly increased in the FA cohort indicating that we can detect chromosome fragility in patients with FA in basal conditions and in a tissue that is divided in vivo. Consequently, the MN assay in exfoliated buccal cells of patients with FA could be used in cancer risk studies and clinical trials aimed to identify cancer chemopreventive drugs.
Identifiants
pubmed: 31830560
pii: S0304-3835(19)30614-7
doi: 10.1016/j.canlet.2019.12.008
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-7Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.